Concept information
Preferred term
Inotuzumab Ozogamicin
Type
-
mesh:Descriptor
Definition
- Immunotoxin that consists of anti-CD22 (CD22 ANTIGEN) humanized monoclonal antibody covalently linked to the antineoplastic antibiotic CALICHEAMICIN. It is used for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (LEUKEMIA, ACUTE LYMPHOBLASTIC).
Broader concept
Entry terms
- P93RUU11P7
Allowable Qualifier(s)
- administration & dosage (Qualifier)
- adverse effects (Qualifier)
- analysis (Qualifier)
- blood (Qualifier)
- cerebrospinal fluid (Qualifier)
- chemistry (Qualifier)
- classification (Qualifier)
- drug effects (Qualifier)
- economics (Qualifier)
- genetics (Qualifier)
- history (Qualifier)
- immunology (Qualifier)
- isolation & purification (Qualifier)
- metabolism (Qualifier)
- pharmacokinetics (Qualifier)
- pharmacology (Qualifier)
- poisoning (Qualifier)
- radiation effects (Qualifier)
- therapeutic use (Qualifier)
- toxicity (Qualifier)
- ultrastructure (Qualifier)
- urine (Qualifier)
Pharmacological Action(s)
In other languages
-
French
-
P93RUU11P7
URI
http://data.loterre.fr/ark:/67375/JVR-KW6VPGBG-S
{{label}}
{{#each values }} {{! loop through ConceptPropertyValue objects }}
{{#if prefLabel }}
{{/if}}
{{/each}}
{{#if notation }}{{ notation }} {{/if}}{{ prefLabel }}
{{#ifDifferentLabelLang lang }} ({{ lang }}){{/ifDifferentLabelLang}}
{{#if vocabName }}
{{ vocabName }}
{{/if}}